title: Selection of possible responders to thrombolytic therapy in acute ischemic stroke.
abstract: Ischemic stroke is one of the leading causes of death and morbidity worldwide, and systemic thrombolytic treatment is still the first-line therapy within 4.5 h from symptom onset. Selecting patients for treatment response is mandatory in any time window but challenging as well. The authors aim to support stroke physicians in their individual decision making. Besides evidence from clinical trials, some suggestions included here exclusively reflect the authors' opinions. This article presents clinical and imaging criteria of selecting patients reasonably, offering causal therapy to a growing number of patients.
authors.affiliation: Department of Neurology, University of Heidelberg, Heidelberg, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Hametner
authors.forename: Peter Arthur
authors.initials: PA
authors.lastname: Ringleb
authors.forename: Werner
authors.initials: W
authors.lastname: Hacke
authors.forename: Lars
authors.initials: L
authors.lastname: Kellert
mesh_terms: D000208:Acute Disease; D015415:Biomarkers; D002545:Brain Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D002533:Cerebral Angiography; D002544:Cerebral Infarction / Q000473:pathology / Q000517:prevention & control; D017326:Clinical Trials, Phase III as Topic; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D015201:Meta-Analysis as Topic; D020768:Middle Cerebral Artery / Q000000981:diagnostic imaging; D015337:Multicenter Studies as Topic; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D015427:Reperfusion Injury / Q000517:prevention & control; D018570:Risk Assessment; D015912:Thrombolytic Therapy; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D005343:Fibrinolytic Agents